ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 530,72
-1,03%
Dow Jones
39 164,06
0,09%
DAX
18 210,55
0,26%
Brent Oil
85,415
1,12%
Bitcoin
61 541,02
1,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lumos Pharma Inc (LUMO)

  7. Lumos Pharma Inc (LUMO) Actualités

LUMO

Lumos Pharma (LUMO)

Lumos Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LUMO
DateHeureSourceTitreSymboleSociété
07/06/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/06/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LUMOLumos Pharma Inc
04/06/202415h00GlobeNewswire Inc.Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024NASDAQ:LUMOLumos Pharma Inc
20/05/202422h05GlobeNewswire Inc.Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024NASDAQ:LUMOLumos Pharma Inc
14/05/202422h15GlobeNewswire Inc.Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsNASDAQ:LUMOLumos Pharma Inc
09/05/202420h51GlobeNewswire Inc.Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024NASDAQ:LUMOLumos Pharma Inc
18/04/202422h05GlobeNewswire Inc.Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsNASDAQ:LUMOLumos Pharma Inc
20/03/202413h00GlobeNewswire Inc.Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042NASDAQ:LUMOLumos Pharma Inc
07/03/202422h48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LUMOLumos Pharma Inc
07/03/202422h01GlobeNewswire Inc.Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateNASDAQ:LUMOLumos Pharma Inc
26/02/202415h00GlobeNewswire Inc.Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024NASDAQ:LUMOLumos Pharma Inc
06/02/202422h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202422h05GlobeNewswire Inc.Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceNASDAQ:LUMOLumos Pharma Inc
11/01/202401h03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
04/01/202422h05GlobeNewswire Inc.Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerNASDAQ:LUMOLumos Pharma Inc
29/11/202322h30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LUMOLumos Pharma Inc
21/11/202322h15GlobeNewswire Inc.Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone DeficiencyNASDAQ:LUMOLumos Pharma Inc
20/11/202322h05GlobeNewswire Inc.Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in NovemberNASDAQ:LUMOLumos Pharma Inc
08/11/202300h24Dow Jones NewsLumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All EndpointsNASDAQ:LUMOLumos Pharma Inc
07/11/202323h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LUMOLumos Pharma Inc
07/11/202322h35GlobeNewswire Inc.Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development UpdatesNASDAQ:LUMOLumos Pharma Inc
07/11/202322h01GlobeNewswire Inc.Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary EndpointsNASDAQ:LUMOLumos Pharma Inc
26/09/202315h00GlobeNewswire Inc.Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual MeetingNASDAQ:LUMOLumos Pharma Inc
14/09/202314h00GlobeNewswire Inc.Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual MeetingNASDAQ:LUMOLumos Pharma Inc
07/09/202322h34GlobeNewswire Inc.Lumos Pharma Announces Participation in Investor Conferences in SeptemberNASDAQ:LUMOLumos Pharma Inc
22/08/202315h00GlobeNewswire Inc.Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic LandscapeNASDAQ:LUMOLumos Pharma Inc
09/08/202322h01GlobeNewswire Inc.Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical UpdateNASDAQ:LUMOLumos Pharma Inc
26/07/202315h00GlobeNewswire Inc.Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023NASDAQ:LUMOLumos Pharma Inc
12/07/202314h00GlobeNewswire Inc.Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences SummitNASDAQ:LUMOLumos Pharma Inc
28/06/202322h01GlobeNewswire Inc.Lumos Pharma Announces Departure of Chief Medical OfficerNASDAQ:LUMOLumos Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LUMO

Dernières Valeurs Consultées

TSX
9229
Sunwels
TSX
GWR
GWR Global Water Resources
TG
A3K1GL
Royal Bank of Canada
COIN
HECEUR
AQSE
AIGL.GB
WisdomTree Commodity Sec...
COIN
WEURUST
TSXV
MDV
Megastar Development
ASX
AQU
LSE
35XB
Paragon M. S47
DBI
I2CG
INAV XTRCK NIKKEI 225 1C...
COIN
PUNKBASICUSD
Punk-Basic
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés